研究单位：[1]CSPC ZhongQi Pharmaceutical Technology Co., Ltd.[2]Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430030
研究目的：
This is a multi-center, open-label, single-arm, phase I/II study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of mitoxantrone hydrochloride liposome injection in subjects with acute myeloid leukemia (AML).
